A trio large pharmas traded units amid continued emphasis on narrowly focused portfolios. Novartis bought a pair of GSK cancer drugs to complement its Gleevec franchise, and in turn sold its vaccines business to GSK while also selling its animal health division to Lilly.
- See more at: http://healthandpharmainsight.tumblr.com/post/83842375761/in-case-you-missed-it#sthash.AjKFLjGO.dpuf
Facebook is jettisoning the chat function from its mobile app as Silicon Valley's cool kids look toward a future of discrete single-function apps that deliver simple, snackable experiences. Thus spake Zuck: on mobile, people want different things. Ease of access is so important. So is having the ability to control which things you get notifications for. And the real estate is so small. In mobile there's a big premium on creating single-purpose first-class experiences. Are there implications for single versus multi-function app design for pharma, or is this just a case of a media giant that would sooner have three revenue streams than one Regardless, big news coming on the heels of Twitter's Facebook-philic redesign and talk of dumping the hashtag!
Genentech inked a big deal with PatientsLikeMe. Where other pharmas have used the crowd-sourced research platform for clinical trials recruitment in a particular disease state, the Genentech's is considerably broader and cuts across categories.